O	0	8	Curcumin	Curcumin	NN	B-NP
O	9	17	inhibits	inhibit	VBZ	B-VP
O	18	28	metastatic	metastatic	JJ	B-NP
O	29	40	progression	progression	NN	I-NP
O	41	43	of	of	IN	B-PP
B-Cell	44	50	breast	breast	NN	B-NP
I-Cell	51	57	cancer	cancer	NN	I-NP
I-Cell	58	62	cell	cell	NN	I-NP
O	63	70	through	through	IN	B-PP
O	71	82	suppression	suppression	NN	B-NP
O	83	85	of	of	IN	B-PP
O	86	95	urokinase	urokinase	NN	B-NP
O	95	96	-	-	HYPH	B-NP
O	96	100	type	type	NN	I-NP
O	101	112	plasminogen	plasminogen	NN	I-NP
O	113	122	activator	activator	NN	I-NP
O	123	125	by	by	IN	B-PP
O	126	128	NF	NF	NN	B-NP
O	128	129	-	-	HYPH	B-NP
O	129	134	kappa	kappa	NN	I-NP
O	135	136	B	B	NN	I-NP
O	137	146	signaling	signaling	NN	I-NP
O	147	155	pathways	pathway	NNS	I-NP
O	155	156	.	.	.	O

O	158	166	Curcumin	Curcumin	NN	B-NP
O	167	168	(	(	(	O
O	168	169	1	1	CD	B-NP
O	169	170	,	,	,	I-NP
O	170	171	7	7	CD	I-NP
O	171	172	-	-	HYPH	O
O	172	175	bis	bis	NN	B-NP
O	175	176	(	(	(	O
O	176	177	4	4	CD	B-NP
O	177	178	-	-	HYPH	I-NP
O	178	185	hydroxy	hydroxy	NN	I-NP
O	185	186	-	-	HYPH	B-NP
O	186	187	3	3	CD	I-NP
O	187	188	-	-	HYPH	I-NP
O	188	201	methoxyphenyl	methoxyphenyl	NN	I-NP
O	201	202	)	)	)	O
O	202	203	-	-	HYPH	B-NP
O	203	204	1	1	CD	I-NP
O	204	205	,	,	,	I-NP
O	205	206	6	6	CD	I-NP
O	206	207	-	-	HYPH	I-NP
O	207	217	heptadiene	heptadiene	NN	I-NP
O	217	218	-	-	HYPH	I-NP
O	218	219	3	3	CD	I-NP
O	219	220	,	,	,	I-NP
O	220	221	5	5	CD	I-NP
O	221	222	-	-	HYPH	I-NP
O	222	227	dione	dione	NN	I-NP
O	227	228	)	)	)	O
O	228	229	,	,	,	O
O	230	232	is	be	VBZ	B-VP
O	233	242	extracted	extract	VBN	I-VP
O	243	247	from	from	IN	B-PP
O	248	251	the	the	DT	B-NP
O	252	257	plant	plant	NN	I-NP
O	258	265	Curcuma	Curcuma	NNP	I-NP
O	266	271	longa	longa	NNP	I-NP
O	271	272	.	.	.	O

O	273	275	It	It	PRP	B-NP
O	276	279	was	be	VBD	B-VP
O	280	288	recently	recently	RB	I-VP
O	289	297	reported	report	VBN	I-VP
O	298	301	for	for	IN	B-PP
O	302	305	its	its	PRP$	B-NP
B-Cancer	306	316	anticancer	anticancer	JJ	I-NP
O	317	323	effect	effect	NN	I-NP
O	324	326	on	on	IN	B-PP
O	327	334	several	several	JJ	B-NP
O	335	340	types	type	NNS	I-NP
O	341	343	of	of	IN	B-PP
B-Cell	344	350	cancer	cancer	NN	B-NP
I-Cell	351	356	cells	cell	NNS	I-NP
O	357	359	in	in	FW	B-ADVP
O	360	365	vitro	vitro	FW	I-ADVP
O	366	373	however	however	RB	I-ADVP
O	373	374	,	,	,	O
O	375	378	the	the	DT	B-NP
O	379	388	molecular	molecular	JJ	I-NP
O	389	399	mechanisms	mechanism	NNS	I-NP
O	400	402	of	of	IN	B-PP
O	403	407	this	this	DT	B-NP
B-Cancer	408	418	anticancer	anticancer	JJ	I-NP
O	419	425	effect	effect	NN	I-NP
O	426	429	are	be	VBP	B-VP
O	430	433	not	not	RB	I-VP
O	434	439	fully	fully	RB	I-VP
O	440	450	understood	understand	VBN	I-VP
O	450	451	.	.	.	O

O	452	454	In	In	IN	B-PP
O	455	458	the	the	DT	B-NP
O	459	466	present	present	JJ	I-NP
O	467	472	study	study	NN	I-NP
O	472	473	,	,	,	O
O	474	476	we	we	PRP	B-NP
O	477	486	evaluated	evaluate	VBD	B-VP
O	487	490	the	the	DT	B-NP
O	491	498	effects	effect	NNS	I-NP
O	499	501	of	of	IN	B-PP
O	502	510	curcumin	curcumin	NN	B-NP
O	511	513	on	on	IN	B-PP
O	514	519	human	human	JJ	B-NP
B-Cell	520	527	mammary	mammary	JJ	I-NP
I-Cell	528	538	epithelial	epithelial	JJ	I-NP
I-Cell	539	548	carcinoma	carcinoma	NN	I-NP
I-Cell	549	552	MCF	MCF	NN	I-NP
I-Cell	552	553	-	-	HYPH	B-NP
I-Cell	553	554	7	7	CD	I-NP
I-Cell	555	560	cells	cell	NNS	I-NP
O	560	561	.	.	.	O

B-Cell	562	567	Cells	Cell	NNS	B-NP
O	568	572	were	be	VBD	B-VP
O	573	580	treated	treat	VBN	I-VP
O	581	585	with	with	IN	B-PP
O	586	594	curcumin	curcumin	NN	B-NP
O	595	598	and	and	CC	O
O	599	607	examined	examine	VBN	B-VP
O	608	611	for	for	IN	B-PP
B-Cell	612	616	cell	cell	NN	B-NP
O	617	626	viability	viability	NN	I-NP
O	627	629	by	by	IN	B-PP
O	630	633	MTT	MTT	NN	B-NP
O	634	639	assay	assay	NN	I-NP
O	639	640	.	.	.	O

O	641	644	The	The	DT	B-NP
B-Cell	645	650	cells	cell	NNS	I-NP
O	651	659	invasion	invasion	NN	I-NP
O	660	663	was	be	VBD	B-VP
O	664	676	demonstrated	demonstrate	VBN	I-VP
O	677	679	by	by	IN	B-PP
O	680	689	transwell	transwell	NN	B-NP
O	690	695	assay	assay	NN	I-NP
O	695	696	.	.	.	O

O	697	700	The	The	DT	B-NP
O	701	708	binding	binding	NN	I-NP
O	709	717	activity	activity	NN	I-NP
O	718	720	of	of	IN	B-PP
O	721	723	NF	NF	NN	B-NP
O	723	724	-	-	HYPH	B-NP
O	724	730	kappaB	kappaB	NN	I-NP
O	731	733	to	to	TO	B-PP
O	734	737	DNA	DNA	NN	B-NP
O	738	741	was	be	VBD	B-VP
O	742	750	examined	examine	VBN	I-VP
O	751	753	in	in	IN	B-PP
B-Organism_substance	754	761	nuclear	nuclear	JJ	B-NP
I-Organism_substance	762	770	extracts	extract	NNS	I-NP
O	771	776	using	use	VBG	B-VP
O	777	782	Trans	Trans	NNP	B-NP
O	782	783	-	-	HYPH	O
O	783	785	AM	AM	NNP	B-NP
O	786	788	NF	NF	NN	I-NP
O	788	789	-	-	HYPH	B-NP
O	789	795	kappaB	kappaB	NN	I-NP
O	796	801	ELISA	ELISA	NN	I-NP
O	802	805	kit	kit	NN	I-NP
O	805	806	.	.	.	O

O	807	814	Western	Western	NN	B-NP
O	815	819	blot	blot	NN	I-NP
O	820	823	was	be	VBD	B-VP
O	824	833	performed	perform	VBN	I-VP
O	834	836	to	to	TO	I-VP
O	837	843	detect	detect	VB	I-VP
O	844	847	the	the	DT	B-NP
O	848	854	effect	effect	NN	I-NP
O	855	857	of	of	IN	B-PP
O	858	866	curcumin	curcumin	NN	B-NP
O	867	869	on	on	IN	B-PP
O	870	873	the	the	DT	B-NP
O	874	884	expression	expression	NN	I-NP
O	885	887	of	of	IN	B-PP
O	888	891	uPA	uPA	NN	B-NP
O	891	892	.	.	.	O

O	893	896	Our	Our	PRP$	B-NP
O	897	904	results	result	NNS	I-NP
O	905	911	showed	show	VBD	B-VP
O	912	916	that	that	IN	B-SBAR
O	917	925	curcumin	curcumin	NN	B-NP
O	926	930	dose	dose	NN	I-NP
O	930	931	-	-	HYPH	B-VP
O	931	942	dependently	dependently	RB	I-VP
O	943	952	inhibited	inhibit	VBN	I-VP
O	953	954	(	(	(	O
O	954	955	P	P	NN	B-NP
O	956	957	<	<	SYM	B-ADJP
O	958	959	0	0	CD	B-NP
O	959	960	.	.	.	I-NP
O	960	962	05	05	CD	I-NP
O	962	963	)	)	)	O
O	964	967	the	the	DT	B-NP
O	968	981	proliferation	proliferation	NN	I-NP
O	982	984	of	of	IN	B-PP
B-Cell	985	988	MCF	MCF	NN	B-NP
I-Cell	988	989	-	-	HYPH	B-NP
I-Cell	989	990	7	7	CD	I-NP
I-Cell	991	996	cells	cell	NNS	I-NP
O	996	997	.	.	.	O

O	998	1007	Meanwhile	Meanwhile	RB	B-ADVP
O	1007	1008	,	,	,	O
O	1009	1012	the	the	DT	B-NP
O	1013	1021	adhesion	adhesion	NN	I-NP
O	1022	1025	and	and	CC	I-NP
O	1026	1034	invasion	invasion	NN	I-NP
O	1035	1042	ability	ability	NN	I-NP
O	1043	1045	of	of	IN	B-PP
B-Cell	1046	1049	MCF	MCF	NN	B-NP
I-Cell	1049	1050	-	-	HYPH	B-NP
I-Cell	1050	1051	7	7	CD	I-NP
I-Cell	1052	1057	cells	cell	NNS	I-NP
O	1058	1062	were	be	VBD	B-VP
O	1063	1070	sharply	sharply	RB	I-VP
O	1071	1080	inhibited	inhibit	VBN	I-VP
O	1081	1085	when	when	WRB	B-ADVP
O	1086	1093	treated	treat	VBN	B-VP
O	1094	1098	with	with	IN	B-PP
O	1099	1108	different	different	JJ	B-NP
O	1109	1123	concentrations	concentration	NNS	I-NP
O	1124	1126	of	of	IN	B-PP
O	1127	1135	curcumin	curcumin	NN	B-NP
O	1135	1136	.	.	.	O

O	1137	1145	Curcumin	Curcumin	NN	B-NP
O	1146	1150	also	also	RB	B-ADVP
O	1151	1164	significantly	significantly	RB	B-VP
O	1165	1174	decreased	decrease	VBN	I-VP
O	1175	1176	(	(	(	O
O	1176	1177	P	P	NN	B-NP
O	1178	1179	<	<	SYM	B-ADJP
O	1180	1181	0	0	CD	B-NP
O	1181	1182	.	.	.	I-NP
O	1182	1184	05	05	CD	I-NP
O	1184	1185	)	)	)	O
O	1186	1189	the	the	DT	B-NP
O	1190	1200	expression	expression	NN	I-NP
O	1201	1203	of	of	IN	B-PP
O	1204	1207	uPA	uPA	NN	B-NP
O	1208	1211	and	and	CC	I-NP
O	1212	1214	NF	NF	NN	I-NP
O	1214	1215	-	-	HYPH	B-NP
O	1215	1221	kappaB	kappaB	NN	I-NP
O	1222	1225	DNA	DNA	NN	I-NP
O	1226	1233	binding	binding	NN	I-NP
O	1234	1242	activity	activity	NN	I-NP
O	1242	1243	,	,	,	O
O	1244	1256	respectively	respectively	RB	B-ADVP
O	1256	1257	.	.	.	O

O	1258	1260	It	It	PRP	B-NP
O	1261	1263	is	be	VBZ	B-VP
O	1264	1273	concluded	conclude	VBN	I-VP
O	1274	1278	that	that	IN	B-SBAR
O	1279	1287	curcumin	curcumin	NN	B-NP
O	1288	1296	inhibits	inhibit	VBZ	B-VP
O	1297	1300	the	the	DT	B-NP
O	1301	1309	adhesion	adhesion	NN	I-NP
O	1310	1313	and	and	CC	I-NP
O	1314	1322	invasion	invasion	NN	I-NP
O	1323	1325	of	of	IN	B-PP
B-Cell	1326	1329	MCF	MCF	NN	B-NP
I-Cell	1329	1330	-	-	HYPH	B-NP
I-Cell	1330	1331	7	7	CD	I-NP
I-Cell	1332	1337	cells	cell	NNS	I-NP
O	1338	1345	through	through	IN	B-PP
O	1346	1350	down	down	RB	B-ADVP
O	1350	1351	-	-	HYPH	O
O	1351	1361	regulating	regulate	VBG	B-VP
O	1362	1365	the	the	DT	B-NP
O	1366	1373	protein	protein	NN	I-NP
O	1374	1384	expression	expression	NN	I-NP
O	1385	1387	of	of	IN	B-PP
O	1388	1391	uPA	uPA	NN	B-NP
O	1392	1395	via	via	IN	B-PP
O	1396	1398	of	of	IN	B-PP
O	1399	1401	NF	NF	NN	B-NP
O	1401	1402	-	-	HYPH	B-NP
O	1402	1408	kappaB	kappaB	NN	I-NP
O	1409	1419	activation	activation	NN	I-NP
O	1419	1420	.	.	.	O

O	1421	1432	Accordingly	Accordingly	RB	B-ADVP
O	1432	1433	,	,	,	O
O	1434	1437	the	the	DT	B-NP
O	1438	1449	therapeutic	therapeutic	JJ	I-NP
O	1450	1459	potential	potential	NN	I-NP
O	1460	1462	of	of	IN	B-PP
O	1463	1471	curcumin	curcumin	NN	B-NP
O	1472	1475	for	for	IN	B-PP
B-Cancer	1476	1482	breast	breast	NN	B-NP
I-Cancer	1483	1489	cancer	cancer	NN	I-NP
O	1490	1498	deserves	deserve	VBZ	B-VP
O	1499	1506	further	further	JJ	B-NP
O	1507	1512	study	study	NN	I-NP
O	1512	1513	.	.	.	O

